What's Happening?
CPHI Milan 2026 focused on the critical issue of pharmaceutical supply chain resilience, with leaders from the US Pharmacopeia (USP) discussing drug shortages, procurement, and digital tools. According to USP's June 2026 annual drug shortages report,
while total shortage events decreased by 23% in 2025, the duration of these shortages increased, and product discontinuations rose by 60% from 2024 to 2025. Michael Levy, Senior Vice President, Digital & Innovation at USP, attributed the rise in discontinuations to upstream fragilities, including natural disasters, geopolitical pressures, and policy changes, rather than solely manufacturing problems. USP CEO Ronald T. Piervincenzi urged manufacturers to proactively address supply chain resilience, emphasizing that waiting for policy changes is not sufficient. He noted that while there is broad support for purchasers to pay for resilience, current systems and information make this difficult. Piervincenzi also highlighted that one resilient supplier is insufficient, as a failure at a less resilient competitor can still cause widespread shortages.
Why It's Important?
The discussions at CPHI Milan underscore a significant challenge for the U.S. healthcare system and its citizens: the fragility of the pharmaceutical supply chain. Prolonged drug shortages can have severe consequences, impacting patient care, increasing healthcare costs, and potentially leading to adverse health outcomes. The call for manufacturers to act proactively, rather than waiting for policy, suggests a recognition that market-driven solutions are essential. The USP's initiative to develop a Drug Supply Chain Resilience Benchmark aims to incentivize resilience by making it a factor in purchasing decisions, which could shift the industry towards more robust practices. For U.S. pharmaceutical companies, this means a potential need to invest more in diversified sourcing, stockpiling, and digital tools to enhance visibility and responsiveness. Consumers stand to gain from a more stable supply of essential medicines, while the healthcare sector could see reduced disruptions and improved patient safety. The emphasis on collective action also highlights that resilience is a shared responsibility across the entire supply chain.
What's Next?
The USP plans to launch its Resiliency Center and develop benchmarks through an open standard-setting process, integrating these into purchasing decisions to make resilience a financially viable investment for manufacturers. This initiative aims to create a market where reliability is rewarded. Manufacturers are encouraged to adopt proactive measures, such as investing in alternative sourcing and maintaining stockpiles, to mitigate future disruptions. There will likely be continued efforts to raise emerging regulatory systems to international standards, potentially broadening sourcing options and reducing dependencies. The pharmaceutical industry is also expected to further embrace digital standards and tools to enhance supply chain visibility and management. Policy discussions, such as Europe's proposed Critical Medicines Act and ongoing 'friendshoring' debates, will continue, but the emphasis remains on industry action to shape these policies rather than merely react to them. The goal is to build a more robust and adaptable pharmaceutical supply chain capable of withstanding future shocks.
Beyond the Headlines
The focus on pharmaceutical supply chain resilience extends beyond immediate drug availability to broader issues of national security and public health infrastructure. The vulnerabilities exposed by recent events, such as the COVID-19 pandemic, have highlighted the strategic importance of a secure and reliable supply of medicines. This could lead to increased government incentives for domestic pharmaceutical manufacturing and a re-evaluation of global sourcing strategies to reduce reliance on potentially unstable regions. Ethically, the discussion raises questions about equitable access to essential medicines, particularly when shortages occur. The concept of 'collective action' in resilience suggests a need for greater collaboration and information sharing among pharmaceutical companies, regulators, and healthcare providers. Furthermore, the integration of digital tools and AI in supply chain management could transform how drugs are tracked, distributed, and managed, potentially leading to more efficient and transparent systems, but also raising concerns about data security and privacy.
